Bridgewater Associates LP bought a new stake in Bausch Health Companies Inc (NYSE:BHC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 169,886 shares of the company’s stock, valued at approximately $4,360,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Andra AP fonden acquired a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $7,039,000. Marshall Wace LLP acquired a new stake in shares of Bausch Health Companies in the second quarter valued at approximately $2,974,000. NEXT Financial Group Inc acquired a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $101,000. Financial Sense Advisors Inc. acquired a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $2,007,000. Finally, Private Management Group Inc. acquired a new stake in shares of Bausch Health Companies in the second quarter valued at approximately $28,474,000. Institutional investors and hedge funds own 50.09% of the company’s stock.
In other Bausch Health Companies news, EVP Christina Ackermann sold 19,946 shares of the firm’s stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $24.98, for a total transaction of $498,251.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Schutter Richard U. De purchased 125,000 shares of the stock in a transaction dated Thursday, September 13th. The shares were purchased at an average price of $23.96 per share, with a total value of $2,995,000.00. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 165,000 shares of company stock valued at $3,890,700. 11.54% of the stock is owned by insiders.
Several research firms recently commented on BHC. Mizuho increased their price target on Bausch Health Companies from $35.00 to $38.00 and gave the company a “buy” rating in a report on Friday. BMO Capital Markets reissued a “hold” rating and set a $26.00 target price on shares of Bausch Health Companies in a research note on Tuesday, November 13th. ValuEngine cut Bausch Health Companies from a “hold” rating to a “sell” rating in a research note on Monday, November 12th. TD Securities raised their target price on Bausch Health Companies from $24.00 to $28.00 and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Finally, Royal Bank of Canada raised their target price on Bausch Health Companies from $30.00 to $31.00 and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $28.18.
BHC stock opened at $24.35 on Monday. The company has a quick ratio of 0.91, a current ratio of 1.14 and a debt-to-equity ratio of 7.55. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 6.16, a price-to-earnings-growth ratio of 0.32 and a beta of -0.28. Bausch Health Companies Inc has a 52-week low of $14.44 and a 52-week high of $28.45.
Bausch Health Companies (NYSE:BHC) last posted its earnings results on Tuesday, November 6th. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.31. The company had revenue of $2.14 billion during the quarter, compared to analysts’ expectations of $2.09 billion. Bausch Health Companies had a positive return on equity of 32.19% and a negative net margin of 40.41%. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities research analysts anticipate that Bausch Health Companies Inc will post 3.81 earnings per share for the current fiscal year.
Bausch Health Companies Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Featured Article: What is a Stop Order?
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.